Erratum in «High rate of virologic supression with darunavir/ritonavir plus optimazed background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil»  by Ernesto Vidal, José et al.
d is . 2013;17(3):387
ian Journal of
S DISEASES
r .com/ locate /b j id
E
E gic supression with
d azed background therapy
a perienced HIV-infected
p ve cohort study in São Paulo,
B
J a, Maria Laura Matosa, Daniel Bartmanna,
G e Mirandaa, Ângela Carvalho Freitasa,
M ac, Aluísio Cotrim Seguradoa,
C Hernándezf
a e São Paulo, São Paulo, SP, Brazil
b Ribas, São Paulo, SP, Brazil
c
d al School, Universidade de São Paulo, São Paulo, SP, Brazil
e eﬁciencies – LIM-56, Department of Dermatology, Medical School,
U
f ute, Cleveland Clinic, Cleveland, USA
I vir/ritonavir plus optimazed background therapy among highly
a prospective cohort study in São Paulo, Brazil”, published in Braz J
I orrections:
PIs: 87 (95)” should read as “Previous use of NRTI, NNRTI and PIs:
9
w
l
9
C
1
hbraz j infect
The Brazil
INFECTIOU
www.elsev ie
rratum
rratum in «High rate of virolo
arunavir/ritonavir plus optim
mong highly antiretroviral-ex
atients: results of a prospecti
razil»
osé Ernesto Vidala,b,∗, Alice Tung Wan Song
uilherme dos Anjosa, Érique José Peixoto d
irian de Freitas Dalbena, Claudinei Santan
láudia Cortese Barretod,e Adrián Vladimir
Department of Infectious Diseases, Medical School, Universidade d
Department of Infectious Diseases, Instituto de Infectologia Emílio
Pharmacy School, Universidade de São Paulo, São Paulo, SP, Brazil
Pro-Blood Foundation/Blood Center of São Paulo (FPS/HSP), Medic
Laboratory of Medical Investigation in Dermatology and Immunod
niversidade de São Paulo, São Paulo, SP, Brazil
Department of Quantitative Health Sciences, Lerner Research Instit
n the article “High rate of virologic supression with daruna
ntiretroviral-experienced HIV-infected patients: results of a
nfect Dis. 2013 Feb;17(1):41-7, please consider the following c
Page 43, Table 1, line 18, “Previous use of NRTI, NNRTI and
2 (100%)”.Page 43, Results section, lines 28-31, “Tenofovir was the most frequent NRTI used (n=83, 90.2%) and its genotyping evaluation
ere: sensitive: 16 (17.4%), intermediate resistance: 8 (8.7%), and resistance: 68 (73.9%).” should read as “All patients received
amivudine and their genotyping evaluation were resistant in all cases. Tenofovir was the second most frequent NRTI used (n=83,
0.2%) and its genotyping evaluation were: sensitive:14 (16.9%), intermediate resistance: 7 (8.4%), and resistance: 62 (74.7%).”
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